Close Menu

BMS

The recent failure of Bristol-Myers Squibb's lung cancer immunotherapy to meet its primary endpoint demonstrates the challenge of working with imperfect biomarkers.

The company also said it has signed a collaboration deal with Bristol-Myers Squibb to evaluate the efficacy of immuno-oncology molecular profiling.

This type of test is intended to help guide personalized treatment, but will doctors order it and payors reimburse it if it's not required for the safe and effective use of a drug?

The test, when used as intended, allows doctors to gauge the magnitude of benefit melanoma patients might derive from the immunotherapeutic Opdivo.

Under the agreement, BMS has access to the 1,310 reagents in the public version of SomaLogic's SOMAscan assay along with a number of custom-developed reagents.

FDA has approved BMS' Opdivo with a test to guide treatment strategies, but according to the drug label testing isn't required to identify who should receive the drug.

In the study, called TAPUR, ASCO will give cancer patients who are out of treatment options off-label drugs based on their genomic data and record their outcomes in a registry.

Researchers explored the predictive value of using mismatch repair deficiency and PD-L1 expression to assess which cancer patients are likely to respond to anti-PD-1 treatments.

A blueprint that four drugmakers released during the meeting represents an initial effort to explore the analytical differences between CDx for drugs in the same class.

The companies are collaborating on a companion diagnostic intended to identify best responders to the PD-1 inhibitor.

Pages

A new analysis suggests warming, not the arrival of humans, led to the extinction of the woolly rhinoceros thousands of years ago, the Economist reports.

Chinese health officials uncovered SARS-CoV-2 viral RNA on imported frozen food, but the New York Times reports catching COVID-19 that way would be unlikely.

The UK has ordered 60 million coronavirus vaccine doses from Novavax and 30 million doses from Janssen, according to the Guardian.

In Science this week: machine learning model predicts whether ion channel mutations will cause disease, and more.